Deals channel feed

In pur­suit of ac­ces­si­ble sick­le cell cure, No­var­tis inks $1.5B deal to tap Pre­ci­sion's AR­CUS gene edit­ing tech

3 years ago
Cell/Gene Tx

Ab­b­Vie walks away from Mor­phic deal in af­ter­math of safe­ty sig­nal in pre­clin­i­cal test­ing

3 years ago

Gala­pa­gos CEO Paul Stof­fels bets €225M on a new CAR-T strat­e­gy for the long suf­fer­ing biotech

3 years ago

Pfiz­er nabs $95M stake in Val­ne­va as Ly­me dis­ease vac­cine ap­proach­es piv­otal study

3 years ago
Financing

Rhythm gets sec­ond OK for ge­net­ic obe­si­ty drug Im­civree, swings in­to roy­al­ty deal

3 years ago
Pharma
FDA+

Up­dat­ed: Mer­ck look­ing at Seagen takeover bid in the wake of Clay Sie­gal­l's res­ig­na­tion — re­port

3 years ago
Pharma

Buy­out buzz: Is As­traZeneca hunt­ing a mi­cro-M&A deal on Nas­daq?

3 years ago

Abu Dhabi's health de­part­ment taps Sanofi in clin­i­cal re­search and AI screen­ing deal

3 years ago
Pharma

Gold­man Sachs leads a $300M round in­to a Chi­na biotech uni­corn boast­ing of its AI/ro­bot­ics prowess

3 years ago
R&D

Ex­elix­is taps in­to can­cer an­ti­body dis­cov­er­er out of Swe­den

3 years ago

Pfiz­er's dig­i­tal ther­a­peu­tics part­ner is back, this time in a new col­lab with Eli Lil­ly

3 years ago

One year af­ter wrap­ping PhI, Bio­gen drops ALS drug it bought from Karyopharm for $10M cash

3 years ago

Sh­iono­gi to pro­vide glob­al ac­cess to its an­tibi­otics, with fo­cus on poor coun­tries, as re­sis­tance fears grow

3 years ago
Pharma
Manufacturing

No in­tro­duc­tions nec­es­sary: A TCR up­start with deep-pock­et back­ers part­ners with one of the new play­ers in the hot gene edit­ing field

3 years ago

Mor­phoSys out-li­cens­es two an­ti­bod­ies to se­cre­tive ARCH biotech as it push­es for­ward with lead Con­stel­la­tion work

3 years ago

Organon inks $103M deal for per­tuzum­ab and deno­sum­ab biosim­i­lars

3 years ago
Pharma
Marketing

Zymeworks adds a clas­sic poi­son pill de­fense to the ar­mory as the biotech's board bat­tles hos­tile takeover

3 years ago
Financing

F-Prime-backed start­up hopes to lever­age AI and a su­per­com­put­er to emerge in pro­tein mis­fold­ing field

3 years ago
Startups
R&D

Psy­che­delics start­up Eleu­sis ax­es SPAC deal, but CEO con­fi­dent its IV psilo­cy­bin ther­a­py will en­ter clin­ic next month

3 years ago
Financing

Aim­ing to har­ness the pow­er of mi­to­chon­dria, a Japan­ese start­up nets new fund­ing

3 years ago
Startups
Manufacturing

#BIO22: By the Num­bers: Af­ter the mu­sic died, you can see some en­cour­ag­ing signs on the M&A and li­cens­ing fronts. But where's the big buy-in?

3 years ago

#BIO22: The bear mar­ket may be maul­ing biotech stocks, but the fun­da­men­tals still look good to re­al es­tate de­vel­op­ers

3 years ago
Financing

#BIO22: Are biotech buy­outs fi­nal­ly com­ing in­to vogue? Here's what to look for in H2 M&A

3 years ago
Financing

Sam­sung Bi­o­log­ics and No­var­tis ink man­u­fac­tur­ing con­tract worth $81M

3 years ago
Manufacturing
First page Previous page 57585960616263 Next page Last page
A service from the Financial Times